This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA). Primary objective: To evaluate the performance characteristics of the blood ctDNA test in early detecting cancers. Secondary objectives: * To evaluate the performance characteristics of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests. * To determine the risk of cancers development in the high-risk population, as compared to that in the moderate-risk group.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Positive predictive value, Negative predictive value of the blood ctDNA test in early detecting cancers
Timeframe: 12 months following enrolment
Sensitivity and specificity of the test in early detecting cancers
Timeframe: 12 months following enrolment